Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program

BACKGROUND: Canagliflozin is approved for glucose lowering in type 2 diabetes and confers cardiovascular and renal benefits. We sought to assess whether it had benefits in people with chronic kidney disease, including those with an estimated glomerular filtration rate (eGFR) between 30 and 45 mL/min...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Circulation
Autors principals: Neuen, Brendon L., Ohkuma, Toshiaki, Neal, Bruce, Matthews, David R., de Zeeuw, Dick, Mahaffey, Kenneth W., Fulcher, Greg, Desai, Mehul, Li, Qiang, Deng, Hsiaowei, Rosenthal, Norm, Jardine, Meg J., Bakris, George, Perkovic, Vlado
Format: Artigo
Idioma:Inglês
Publicat: Lippincott Williams & Wilkins 2018
Matèries:
Original Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6181277/
https://ncbi.nlm.nih.gov/pubmed/29941478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.118.035901
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars